Genomic methylation profiling combined with gene expression microarray reveals the aberrant methylation mechanism involved in nasopharyngeal carcinoma taxol resistance
- 1 September 2012
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Anti-Cancer Drugs
- Vol. 23 (8), 856-864
- https://doi.org/10.1097/cad.0b013e3283548d73
Abstract
Taxol is a first-line chemoagent used for treatment of nasopharyngeal carcinoma (NPC). A major obstacle to achieving successful treatment is the development of cellular taxol drug resistance. Aberrant DNA methylation has been recognized to be associated with the transcriptional inactivation of genes related to cancer drug resistance development. To identify the mechanism of DNA methylation involved in NPC taxol resistance, we applied a genome-wide DNA methylation microarray assay to reveal methylation alteration in taxol-resistant NPC cell lines (CNE-1/taxol, 5–8F/taxol, HNE-2/taxol) established previously in our laboratory. Combining with gene expression microarray, we identified drug resistance-associated genes in taxol-resistant cell lines. We also investigated the coeffect of taxol and the DNA methyltransferase inhibitor 5-aza-2′-deoxycytidine (5-aza-dC) to confirm the involvement of DNA methylation. The methylation profiling revealed differential patterns between the drug-sensitive and -resistant cell lines. As a result, taxol-resistant cell lines were detected to be globally hypermethylated. Forty-eight differentially methylated genes (30 hypermethylated and 18 hypomethylated) were further identified commonly in the three taxol-resistant cell lines. Six of them (DLC1, CHFR, ABCC5, PEG10, ERBB2, and GSTP1) were independently confirmed to contribute to taxol resistance by both methylation-specific PCR and quantitative real-time PCR. Finally, we conclude that DNA methylation is closely correlated with taxol drug resistance in NPC cells. Combined analysis of DNA methylation and gene expression may enable the discovery of new therapeutic targets and prognostic biomarkers of cancers. Furthermore, DNA methylation inhibitors can reverse chemoresistance and prevent the development of acquired drug resistance.Keywords
This publication has 30 references indexed in Scilit:
- Reversal of taxol resistance by cisplatin in nasopharyngeal carcinoma by upregulating thromspondin-1 expressionAnti-Cancer Drugs, 2010
- Association of GSTP1 expression with resistance to docetaxel and paclitaxel in human breast cancersEuropean Journal of Surgical Oncology, 2008
- Paclitaxel: a review of adverse toxicities and novel delivery strategiesEnvironment, Development and Sustainability, 2007
- Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cellsNature Genetics, 2005
- Nasopharyngeal carcinomaThe Lancet, 2005
- The epigenetics of ovarian cancer drug resistance and resensitizationAmerican Journal of Obstetrics and Gynecology, 2004
- Epigenetic regulation of the taxol resistance–associated gene TRAG-3 in human tumorsCancer Genetics and Cytogenetics, 2004
- Mechanisms of Taxol resistance related to microtubulesOncogene, 2003
- Communication between Multiple Drug Binding Sites on P-glycoproteinMolecular Pharmacology, 2000
- The role of chemotherapy in the management of nasopharyngeal carcinomaCancer, 1998